Suppr超能文献

随机临床试验——我是我兄弟的守护者吗?

Randomized clinical trials--am I by brother's keeper?

作者信息

Katz J

出版信息

J Clin Gastroenterol. 1981;3(Suppl 2):141-6.

PMID:7320464
Abstract

If reasonable effective therapy for a disease is available, is it then ethical to conduct placebo-controlled studies with other unproven, but potentially beneficial, agents? Some investigators prefer to use proven-therapy controls when evaluating new drugs; however, random tests done with a placebo provide more accurate results. Therefore, when may society expose some human beings to potential harm in order to seek future benefits for society as a whole? A study done by Peterson and Elashoff suggested that a placebo-controlled trials is "clearly unethical" because the patient-subjects are a "high risk," and that "informed consent" becomes a fiction because no patient who clearly understood the implications of these trials would consent. Subjects; preferences have not been given much weight. Chalmers and associates maintain that randomization studies, which have also neglected patients' preferences, are more ethical than testing new therapies in an unscientific manner. Chalmers and others stressed that the physician must believe that he has "no knowledge at all that one treatment will be better or worse, safer or more dangerous than another." Some feel that active participation by patients would expose them to greater-than-warranted risks. The FDA has stated that informed consent should be obtained from each subject or representative before he or she may participate in clinical investigation. We suggest that only the patient and investigator make the decision to participate in a joint undertaking, not the profession or the state. This will require an open dialogue between physicians and patients, with each group taking responsibility for themselves and for each other.

摘要

如果针对某种疾病已有合理有效的治疗方法,那么开展使用其他未经证实但可能有益的药物进行安慰剂对照研究是否合乎伦理道德呢?一些研究人员在评估新药时更倾向于使用已证实的治疗方法作为对照;然而,使用安慰剂进行的随机试验能提供更准确的结果。那么,为了为整个社会谋求未来的利益,社会在何时可以让一些人面临潜在的伤害呢?彼得森和埃拉肖夫所做的一项研究表明,安慰剂对照试验“显然不道德”,因为受试患者处于“高风险”中,而且“知情同意”也成了一纸空文,因为没有哪个清楚了解这些试验影响的患者会同意。受试者的偏好并未得到足够重视。查尔默斯及其同事坚持认为,同样忽视了患者偏好的随机化研究比以不科学的方式测试新疗法更符合伦理道德。查尔默斯等人强调,医生必须相信他“根本不知道一种治疗方法会比另一种更好或更差、更安全或更危险”。有些人认为患者的积极参与会使他们面临超出合理范围的风险。美国食品药品监督管理局表示,在每个受试者或其代表参与临床研究之前,都应获得其知情同意。我们建议,只有患者和研究者共同决定是否参与一项联合试验,而不是由行业或政府来决定。这将需要医生和患者之间进行公开对话,双方各自为自己和对方负责。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验